Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

PHASE1RecruitingINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2029

Conditions

Solid Tumor

Interventions

DRUG

CBP-1019

Given by vein (IV)

DRUG

Oxaliplatin

Given by vein (IV)

DRUG

Leucovorin

Given by vein (IV)

DRUG

5-FLUOROURACIL

Given by vein (IV)

DRUG

Bevacizumab

Given by vein (IV)

DRUG

Pembrolizumab

Given by vein (IV)

DRUG

Enzalutamide

Given by mouth

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER